Results from this investigation indicated that the peptide reduced over 50% body weight gain of the animals in comparison with the control. Further observation indicated heightened lipolytic activity within the adipose tissues of rats receiving AOD 9604 peptide, accompanied by an absence of notable disruptions in insulin sensitivity
5-Amino-1MQ and GLP-1 agonists (like semaglutide) work through fundamentally different mechanisms
This is the window that the Finkley 2005 trial captured, and the Carey/Pickart ultrasound work confirmed at the structural level: an average 28% increase in collagen density, with top responders at 51%
Success requires physician supervision, objective body composition monitoring (not just scale weight), and integration with proper nutrition and exercise foundations for optimal metabolic outcomes
However, both peptides were effective, and the difference was not large
Patients typically receive injections once or twice weekly for the first two weeks, followed by monthly maintenance doses, making the treatment cost-effective for those requiring consistent B12 supplementation
